






Advances in HCV Therapeutics Therapeutic strategies currently under investigation (I) High dose PEG-IFN induction for genotype 1 (CHARIOT) Longer duration of PEG/RBV (72 wks) for genotype 1 Shorter duration of PEG/RBV (16 wks) for genotype 2/3 High individualized RBV dosing Long-term low dose PEG-IFN in non-responders (HALT-C)

















Advances in HCV Therapeutics



Protease Inhibitor - BILN 2061

- NS3/4A protease inhibitor
- First small molecule agent to demonstrate HCV antiviral activity
- Active in inhibiting HCV RNA replicons in cultured cells
- Phase I clinical trial (genotype 1)
 200mg bd for 2 days
 2-3 log reduction in HCV RNA within 48 hours
- Further toxicology (animals) at higher doses demonstrated cardiac toxicity
- ?? Resistance

Advances in HCV Therapeutics



Strategies for increased access to HCV treatment

- Increasing awareness of improved treatment response
- Broadened base of practitioners involved in HCV care
- Multidisciplinary clinics
- Enhanced clinical trial infrastructure
- Research on most appropriate treatment delivery models
- Removal of liver biopsy requirement
- Advocacy